- Home
- ORIO vs INAB Comparison
ORIO vs INAB Comparison
Compare ORIO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIO | INAB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 22.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORIO | INAB |
|---|---|---|
| Price | $1.32 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | 121.2K | ★ 133.3K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $29,215,516.00 | N/A |
| Revenue This Year | $63.05 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $5.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $1.17 |
| 52 Week High | $3.83 | $12.53 |
Technical Indicators
Market Signals| Indicator | ORIO | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 76.25 | 47.37 |
| Support Level | $1.08 | $2.30 |
| Resistance Level | $1.38 | $2.73 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 80.61 | 13.62 |
Price Performance
Historical ComparisonAbout ORIO Orion Digital Corp. Common Shares
Orion Digital Corp is a digital finance company operating across wealth, payments, and digital assets. Through its Investing wealth platform, Carta World-wide payments infrastructure, and long-duration Bitcoin treasury plan - combined with a disciplined, multi-engine compounding model. Orion Digital is focused on compounding value through execution, scale, and capital discipline.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.